Standard BioTools
LAB
97 hedge funds and large institutions have $246M invested in Standard BioTools in 2016 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 32 increasing their positions, 32 reducing their positions, and 13 closing their positions.
8% more capital invested
Capital invested by funds: $229M → $246M (+$17.3M)
0% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 32
3% less call options, than puts
Call options by funds: $526K | Put options by funds: $545K
3% less funds holding
Funds holding: 100 → 97 (-3)
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCS
Levin Capital Strategies
New York
|
+$14.1M |
| 2 |
Renaissance Technologies
New York
|
+$1.43M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$1.41M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.12M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$10.6M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$7.03M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.9M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$2.7M |
| 5 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$2.62M |
LAB Hedge Fund Activity: Q2 2016 in Review
97 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q2 2016, worth a combined $246M — up 7.6% from $229M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of LAB and 11 opened new positions — a net loss of 2 holders — while 32 trimmed existing stakes and 32 added.
The largest buyer was Levin Capital Strategies, adding an estimated $14.1M. The largest seller was Jennison Associates, cutting an estimated $10.6M.
- 97 institutional investors held Standard BioTools (LAB) as of Q2 2016, down from 100 in Q1 2016.
- Funds reported $246M of Standard BioTools stock for Q2 2016, up 7.6% quarter-over-quarter.
- 11 funds opened new Standard BioTools positions in Q2 2016 and 13 closed out, a net change of -2 holders.
- The largest Standard BioTools buyer in Q2 2016 was Levin Capital Strategies, an estimated $14.1M added.
- The largest Standard BioTools seller in Q2 2016 was Jennison Associates, an estimated $10.6M sold.
Based on aggregated 13F filings for Q2 2016.